MCID: MYL003
MIFTS: 48

Myeloid Sarcoma

Categories: Blood diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myeloid Sarcoma

MalaCards integrated aliases for Myeloid Sarcoma:

Name: Myeloid Sarcoma 11 19 58 14 16 75 31 33
Granulocytic Sarcoma 11 19 58 16 71 33
Chloroma 11 19 58 33
Extramedullary Myeloid Tumor 11 19 58
Myeloid Sarcoma Without Mention of Remission 33
Myeloid Sarcoma Disease 33
Sarcoma, Granulocytic 75
Sarcoma Granulocytic 53
Myeloid Sarcoma Nos 33
Sarcoma, Myeloid 43
Myelosarcoma 33

Characteristics:


Prevelance:

<1/1000000 (Europe) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:8683
MeSH 43 D023981
NCIt 49 C35815
SNOMED-CT 68 188738007
ICD10 31 C92.3
MESH via Orphanet 44 D023981
ICD10 via Orphanet 32 C92.3
UMLS via Orphanet 72 C0152276
Orphanet 58 ORPHA86850
ICD11 33 1988933820
UMLS 71 C0152276

Summaries for Myeloid Sarcoma

GARD: 19 Myeloid sarcoma is a rare solid tumor of the myelogenous cells occurring in an extramedullary site.

MalaCards based summary: Myeloid Sarcoma, also known as granulocytic sarcoma, is related to acute myelomonocytic leukemia and acute myeloid leukemia with t(8;21)(q22;q22) translocation. An important gene associated with Myeloid Sarcoma is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and NF-kappaB Signaling. The drugs Etoposide and Asparaginase Escherichia coli have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone marrow and bone, and related phenotypes are immune system and neoplasm

Orphanet: 58 Myeloid sarcoma is a rare solid tumor of the myelogenous cells occurring in an extramedullary site.

Wikipedia: 75 A myeloid sarcoma (chloroma, granulocytic sarcoma,: 744 extramedullary myeloid tumor) is a solid tumor... more...

Related Diseases for Myeloid Sarcoma

Diseases related to Myeloid Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 630)
# Related Disease Score Top Affiliating Genes
1 acute myelomonocytic leukemia 31.8 MPO KMT2A KIT FLT3 DNTT
2 acute myeloid leukemia with t(8;21)(q22;q22) translocation 31.8 RUNX1T1 KIT FLT3
3 acute myeloblastic leukemia with maturation 30.7 NPM1 KIT FLT3
4 myeloproliferative neoplasm 30.7 U2AF1 MPO KMT2A KIT FLT3 CD34
5 essential thrombocythemia 30.4 U2AF1 KIT FLT3 CD34
6 acute myeloblastic leukemia without maturation 30.4 NPM1 FLT3
7 mastocytosis 30.3 TNFRSF8 KIT FLT3
8 mast cell neoplasm 30.3 U2AF1 KIT FLT3
9 orbital cancer 30.3 NCAM1 CD68 CD34
10 embryonal rhabdomyosarcoma 30.2 PTPRC NCAM1 CD34
11 thymus cancer 30.2 PTPRC KIT DNTT
12 aplastic anemia 30.1 U2AF1 MPO FLT3 CD34
13 myelofibrosis 30.1 U2AF1 NPM1 MPO KIT FLT3 CD34
14 jejunal neoplasm 30.1 KIT CD34
15 polycythemia vera 30.1 U2AF1 PTPRC MPO KIT
16 myelophthisic anemia 30.1 U2AF1 CD34 ANPEP
17 myeloid leukemia 30.1 U2AF1 RUNX1T1 NPM1 NCAM1 MPO KMT2A
18 acute erythroid leukemia 30.1 U2AF1 KIT FLT3 CD34
19 chronic eosinophilic leukemia 30.1 U2AF1 KIT FLT3
20 histiocytosis 30.1 U2AF1 TNFRSF8 PTPRC
21 breast sarcoma 30.0 KIT CD34
22 childhood acute lymphocytic leukemia 30.0 KMT2A FLT3 ANPEP
23 breast malignant phyllodes tumor 30.0 KIT CD34
24 anaplastic large cell lymphoma 30.0 TNFRSF8 PTPRC NPM1
25 vagina sarcoma 30.0 KIT CD34
26 myelodysplastic/myeloproliferative neoplasm 29.9 U2AF1 NPM1 KIT FLT3 CD34
27 connective tissue benign neoplasm 29.9 KIT CD68 CD34
28 orbital disease 29.9 NCAM1 MPO CD68 CD34
29 chronic lymphocytic leukemia/small lymphocytic lymphoma 29.9 TNFRSF8 SPN CD79A
30 lymphoma, hodgkin, classic 29.9 TNFRSF8 PTPRC IRF4 CD68
31 mastocytosis, cutaneous 29.8 U2AF1 TNFRSF8 KIT CD34
32 meninges sarcoma 29.8 IRF4 CD34
33 lymphoplasmacytic lymphoma 29.8 SPN IRF4 CD79A
34 fibrosarcoma of bone 29.7 TNFRSF8 CD79A CD68
35 langerhans cell histiocytosis 29.7 U2AF1 TNFRSF8 CD68 CD34
36 leukemia, acute monocytic 29.7 U2AF1 MPO KMT2A FLT3 CD33
37 leukemia 29.7 U2AF1 RUNX1T1 NPM1 KMT2A KIT FLT3
38 chronic myelomonocytic leukemia 29.6 U2AF1 NPM1 MPO KIT FLT3 CD34
39 aleukemic leukemia cutis 29.6 SPN NPM1 MPO CD34 ANPEP
40 germ cell cancer 29.6 TNFRSF8 KIT FUT4 CD34
41 lymphoblastic lymphoma 29.5 TNFRSF8 PTPRC MPO KMT2A DNTT CD7
42 hodgkin's lymphoma, nodular sclerosis 29.5 TNFRSF8 FUT4 CD79A
43 core binding factor acute myeloid leukemia 29.5 U2AF1 RUNX1T1 NPM1 KIT FLT3
44 lymphoma 29.5 TNFRSF8 PTPRC NPM1 IRF4 DNTT ANPEP
45 childhood acute myeloid leukemia 29.5 U2AF1 RUNX1T1 NPM1 KMT2A KIT FLT3
46 ewing sarcoma 29.5 TNFRSF8 PTPRC NCAM1 KIT DNTT
47 peripheral t-cell lymphoma 29.5 TNFRSF8 PTPRC NCAM1 CD7
48 plasmacytoma 29.4 PTPRC NCAM1 IRF4 CD79A
49 central nervous system leukemia 29.4 KMT2A CD7 CD34 CD33 ANPEP
50 diffuse large b-cell lymphoma 29.3 U2AF1 TNFRSF8 IRF4 CD79A

Graphical network of the top 20 diseases related to Myeloid Sarcoma:



Diseases related to Myeloid Sarcoma

Symptoms & Phenotypes for Myeloid Sarcoma

GenomeRNAi Phenotypes related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 ANPEP CD33 CD34 CD68 CD7 CD79A
2 no effect GR00402-S-2 10.19 ANPEP CD34 CD68 CD7 CD79A DNTT

MGI Mouse Phenotypes related to Myeloid Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.91 ANPEP CD33 CD34 CD68 CD7 CD79A
2 neoplasm MP:0002006 9.85 CD34 CD79A FLT3 IRF4 KIT KMT2A
3 hematopoietic system MP:0005397 9.58 ANPEP CD33 CD34 CD68 CD7 CD79A

Drugs & Therapeutics for Myeloid Sarcoma

Drugs for Myeloid Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3 33419-42-0 36462
2
Asparaginase Escherichia coli Approved, Investigational Phase 3 9015-68-3
3
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
4
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239
5
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
6
Daunorubicin Approved Phase 3 20830-81-3 30323
7
Mitoxantrone Approved, Investigational Phase 3 70476-82-3, 65271-80-9 4212
8
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
9
Asparagine Approved, Investigational, Nutraceutical Phase 3 70-47-3 6267
10 Analgesics Phase 3
11 Antimitotic Agents Phase 3
12
Etoposide phosphate Phase 3 16760419
13 Keratolytic Agents Phase 3
14 Tubulin Modulators Phase 3
15 N-Methylaspartate Phase 3
16 Dermatologic Agents Phase 3
17 Protein Kinase Inhibitors Phase 3
18
Blinatumomab Approved, Investigational Phase 2 853426-35-4
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
20
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
21
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
22
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
23
Idarubicin Approved Phase 2 58957-92-9 42890
24
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
25
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
26
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
27
Melphalan Approved Phase 2 148-82-3 4053 460612
28
Rituximab Approved Phase 2 174722-31-7
29
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
32
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
33
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
34
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
35
Aldesleukin Approved Phase 2 110942-02-4
36
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
37
Busulfan Approved, Investigational Phase 2 55-98-1 2478
38
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704
39
Plerixafor Approved Phase 2 110078-46-1 65015
40
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42
Lipoic acid Approved, Investigational, Nutraceutical Phase 2 1200-22-2 864 6112
43
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 2 63-91-2, 673-06-3 6140 71567
44
Cordycepin Investigational Phase 2 73-03-0 248010
45 Antifungal Agents Phase 2
46 Cardiotonic Agents Phase 2
47
Razoxane Phase 2
48 Immunoglobulins Phase 2
49 2'-deoxyadenosine Phase 2
50 2-chloro-3'-deoxyadenosine Phase 2 14485373

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD Active, not recruiting NCT01371981 Phase 3 Asparaginase;Bortezomib;Cytarabine;Daunorubicin Hydrochloride;Etoposide;Mitoxantrone Hydrochloride;Sorafenib Tosylate
2 Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting NCT02790515 Phase 2 Anti-thymocyte globulin (rabbit);Blinatumomab;Cyclophosphamide;Fludarabine;G-CSF;Melphalan;Mesna;Rituximab;Tacrolimus;Thiotepa;Sirolimus
3 Cardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms Recruiting NCT03589729 Phase 2 Cladribine;Cytarabine;Dexrazoxane Hydrochloride;Gemtuzumab Ozogamicin;Idarubicin
4 Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML Active, not recruiting NCT02658487 Phase 2 Cytarabine;Vosaroxin
5 An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Active, not recruiting NCT02484391 Phase 2 6,8-Bis(benzylthio)octanoic Acid;Cytarabine;Mitoxantrone Hydrochloride
6 CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Terminated NCT02259348 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Thiotepa;Rituximab
7 T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant Terminated NCT01621477 Phase 2 clofarabine;cytarabine;busulfan;Plerixafor;cyclophosphamide;antithymocyte globulin (rabbit);Tacrolimus;mycophenolate mofetil
8 A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies Recruiting NCT04521946 Phase 1 Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus;Thiotepa

Search NIH Clinical Center for Myeloid Sarcoma

Cochrane evidence based reviews: sarcoma, myeloid

Genetic Tests for Myeloid Sarcoma

Anatomical Context for Myeloid Sarcoma

Organs/tissues related to Myeloid Sarcoma:

MalaCards : Myeloid, Bone Marrow, Bone, T Cells, Breast, Spinal Cord, Small Intestine

Publications for Myeloid Sarcoma

Articles related to Myeloid Sarcoma:

(show top 50) (show all 2397)
# Title Authors PMID Year
1
The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas. 53 62
18794057 2008
2
Preceding orbital granulocytic sarcoma in an adult patient with acute myelogenous leukemia with t(8;21): a case study and review of the literature. 53 62
18656695 2008
3
t(5;12)(q13;p13) in acute myeloid leukemia with preceding granulocytic sarcoma. 53 62
17854675 2007
4
Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literature. 53 62
17700206 2007
5
Granulocytic sarcoma of breast: an aleukemic presentation. 53 62
17337816 2007
6
Myeloid sarcoma occurring concurrently with drug-induced gingival enlargement. 53 62
16579712 2006
7
Rearrangement of MLL in a patient with congenital acute monoblastic leukemia and granulocytic sarcoma associated with a t(1;11)(p36;q23) translocation. 53 62
15621793 2005
8
[A-leukemic caecal myeloid sarcoma: a difficult diagnosis]. 53 62
15738870 2004
9
FLT3 mutations in myeloid sarcoma. 53 62
15352981 2004
10
Extramedullary presentation of acute leukaemia: a case of myeloid/natural killer cell precursor leukaemia. 53 62
12959763 2003
11
Granulocytic sarcoma in MLL-positive infant acute myelogenous leukemia: fluorescence in situ hybridization study of childhood acute myelogenous leukemia for detecting MLL rearrangement. 53 62
11733351 2001
12
c-Kit (CD117) reactivity in extramedullary myeloid tumor/granulocytic sarcoma. 53 62
11698000 2001
13
The value of CD34, myeloperoxidase and chloroacetate esterase (Leder) stain in the diagnosis of granulocytic sarcoma. 53 62
17261930 2001
14
[Granulocytic sarcoma presenting as an epidural mass with spinal cord compression]. 53 62
11020993 2000
15
CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature. 53 62
11138613 2000
16
Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. 53 62
8902835 1996
17
Granulocytic sarcoma with expression of CD30. 53 62
9038763 1996
18
Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. 53 62
8907283 1996
19
Extramedullary tumors of lymphoid or myeloid blasts. The role of immunohistology in diagnosis and classification. 53 62
7572794 1995
20
Myelodysplastic syndrome presenting with generalized cutaneous granulocytic sarcomas. 53 62
2154905 1990
21
Immunohistochemical differential diagnosis of granulocytic sarcomas and malignant lymphomas on formalin-fixed material. 53 62
2106752 1990
22
18 F-FDG PET/CT Findings of Myeloid Sarcoma Involving the Left Ventricle and Kidney in a Pediatric Patient. 62
36179330 2023
23
Breast manifestation of extramedullary myeloid sarcoma: A case report. 62
36204411 2022
24
Acute subdural hematoma due to acute myeloid leukemia and B-cell lymphoma. 62
36164337 2022
25
Myeloid sarcoma mimicking suprasellar meningioma in acute promyelocytic leukaemia. 62
35249746 2022
26
Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof-of-concept case study. 62
36354135 2022
27
Myeloid Sarcoma: Features in Cytological Preparations and the Utility of Rapid On-Site Evaluation (ROSE) in Triage. 62
36318898 2022
28
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. 62
36107670 2022
29
Successful Treatment of Pediatric Acute Myeloid Leukemia Presenting with Hyperbilirubinemia Secondary to Myeloid Sarcoma: A Case Report. 62
36360428 2022
30
Granulocytic sarcoma with long spinal cord compression: A case report. 62
36387816 2022
31
[Isolated myeloid sarcoma of the cervix: a clinicopathological analysis of three cases]. 62
36323550 2022
32
Myeloid sarcoma: "A cytological surprise". 62
35960136 2022
33
Myeloid sarcoma with ulnar nerve entrapment: A case report. 62
36246824 2022
34
Isolated myeloid sarcoma with pericardial and pleural effusions as first manifestation: A case report. 62
36281103 2022
35
[Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation]. 62
36208236 2022
36
TCL-525 Salivary Myeloid Sarcoma: A Challenging Diagnosis. 62
36164135 2022
37
Myeloid sarcoma arising at the uterine cervix in a patient with intestinal Behçet's disease and concurrent myelodysplastic syndrome: A case report. 62
36316914 2022
38
A clinical report of intracranial granulocytic sarcoma and a literature review. 62
33272089 2022
39
Serial Analysis and Comparison of Mutation Profiles in Decitabine-treated Myeloid Sarcoma and Subsequent Acute Myeloid Leukemia Using Next-Generation Sequencing. 62
35470279 2022
40
A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm. 62
35217871 2022
41
Presentation of Chloromas in B-Mode Ultrasound and Contrast-Enhanced Ultrasound. 62
35778304 2022
42
Identification of RCC1-LCK as a novel fusion gene in pediatric erythroid sarcoma. 62
35714314 2022
43
A ZBTB16-RARα Variant of Acute Promyelocytic Leukemia with Concurrent Myeloid Sarcoma Presenting as Sudden Onset Paraplegia. 62
36125151 2022
44
Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA presenting as myeloid sarcoma. 62
36051048 2022
45
Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia. 62
35949412 2022
46
Myeloid sarcoma of the breast as a first manifestation of acute myeloid leukemia: A case report. 62
35414450 2022
47
Clinicopathological characteristics, genetics and prognosis of patients with myeloid sarcoma: a single-center study. 62
35927017 2022
48
Vulvovaginal myeloid sarcoma with massive pelvic floor infiltration: A case report and review of literature. 62
36159511 2022
49
The characteristics and prognostic significance of the SET-CAN/NUP214 fusion gene in hematological malignancies: A systematic review. 62
35905214 2022
50
Bilateral Orbital Myeloid Sarcomas: A Unique Presentation of Acute Myeloid Leukemia. 62
36051742 2022

Variations for Myeloid Sarcoma

Expression for Myeloid Sarcoma

Search GEO for disease gene expression data for Myeloid Sarcoma.

Pathways for Myeloid Sarcoma

GO Terms for Myeloid Sarcoma

Cellular components related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.16 ANPEP CD33 CD34 CD68 CD7 CD79A
2 membrane GO:0016021 10.16 ANPEP CD33 CD34 CD68 CD7 CD79A
3 external side of plasma membrane GO:0009897 9.53 SPN PTPRC NCAM1 KIT CD79A CD34

Biological processes related to Myeloid Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell activation GO:0042110 9.8 PTPRC IRF4 CD7
2 myeloid progenitor cell differentiation GO:0002318 9.46 KIT FLT3
3 positive regulation of response to stimulus GO:0048584 9.37 KIT FLT3
4 positive regulation of protein modification process GO:0031401 9.26 KIT FLT3
5 positive regulation of protein tyrosine phosphatase activity GO:1903615 9.26 PTPRC CD33
6 B cell differentiation GO:0030183 9.23 PTPRC KIT FLT3 CD79A

Sources for Myeloid Sarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....